Receives undisclosed milestone payment
Australian drug discovery company Phylogica has achieved the initial research objectives of its collaboration with Roche.
The aim of the first stage of the research was to use Phylogica’s Phylomer drug discovery platform to identify novel cell-penetrating peptides for targeting intracellular disease pathways. Roche has now independently validated the cell penetration activities of the Phylomers discovered by Phylogica and the two companies will expand their collaboration to include in vivo studies for identification of unique Phylomer peptides that cross the blood-brain barrier. The objective of such delivery is to develop new treatments for neurological disorders using biologics.
Phylogica will receive an undisclosed milestone payment to reflect the completion of the first stage of the collaboration with Roche.